ストックスクリーナーアプリを入手
2.92
3.18%
0.09
アフターアワーズ：
2.88
-0.04
-1.37%
前日終値:
$2.83
開ける：
$2.83
24時間の取引高:
4.84M
Relative Volume:
1.90
時価総額：
$321.73M
収益：
$35.95M
当期純損益:
$-104.99M
株価収益率:
-2.1523
EPS:
-1.3567
ネットキャッシュフロー:
$-99.30M
1週間 パフォーマンス:
+1.39%
1か月 パフォーマンス:
+8.15%
6か月 パフォーマンス:
+11.88%
1年 パフォーマンス:
+79.14%
1日の値動き範囲:
$2.75
$3.085
1週間の範囲:
$2.52
$3.085
52週間の値動き範囲:
$1.21
$3.82
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Compare CCCC vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.92 | 311.81M | 35.95M | -104.99M | -99.30M | -1.3567 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 108.71B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 74.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.61B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 41.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.81B | 5.36B | 287.73M | 924.18M | 2.5229 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-02 | 開始されました | TD Cowen | Buy |
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-15 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2024-12-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 開始されました | Stephens | Equal-Weight |
| 2024-01-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-12-13 | アップグレード | Stifel | Hold → Buy |
| 2023-02-24 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-11-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Underweight |
| 2022-04-28 | 開始されました | Credit Suisse | Underperform |
| 2022-04-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-10 | 開始されました | JP Morgan | Overweight |
| 2022-02-11 | 再開されました | BMO Capital Markets | Outperform |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-11-23 | 開始されました | BofA Securities | Buy |
| 2021-10-14 | 開始されました | SVB Leerink | Mkt Perform |
| 2021-09-30 | 開始されました | Stifel | Hold |
| 2021-06-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-10-27 | 開始されました | BMO Capital Markets | Outperform |
| 2020-10-27 | 開始されました | Jefferies | Buy |
すべてを表示
C 4 Therapeutics Inc (CCCC) 最新ニュース
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
43 new Intellia employees get stock awards worth 208,850 shares - Stock Titan
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update - MarketBeat
C4 Therapeutics prices $125M equity offering with warrants - MSN
Form ARS C4 Therapeutics, Inc. For: Apr 29 - StreetInsider
Form DEFA14A C4 Therapeutics, Inc. - StreetInsider
C4 Therapeutics (NASDAQ: CCCC) outlines 2026 votes and equity plan change - Stock Titan
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
C4 Therapeutics files $400M mixed shelf offering - MSN
CCCC stock gets pre-market boost on Roche tie-up to develop cancer treatments - MSN
[Form 4] Travere Therapeutics, Inc. Insider Trading Activity - Stock Titan
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics deepens Roche alliance to target breakthrough cancer therapies - MSN
CCCC (C4 Therapeutics Inc.) reports narrower than expected Q4 2025 loss, shares tick slightly higher in daily trading. - Cổng thông tin điện tử tỉnh Lào Cai
C4 Thera (CCCC) Stock Interest Rate (-2.88%) 2026-04-22Capital Preservation - UBND thành phố Hải Phòng
Wasatch holds 4.7% stake in C4 Therapeutics (CCCC) via Schedule 13G/A - Stock Titan
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill
Assessing Roche Holding (SWX:ROG) Valuation After New C4 Therapeutics Oncology Partnership - Yahoo Finance
Atrium offers stock awards to 7 new hires under Nasdaq rule - Stock Titan
Analysts see significant upside in C4 Therapeutics (CCCC) stock - MSN
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Short Interest in C4 Therapeutics, Inc. (NASDAQ:CCCC) Grows By 19.4% - MarketBeat
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
New PTC hire gets stock awards priced at $70.42 a share - Stock Titan
Stoke Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice - Eastern Progress
Acrivon Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 14, 2026 - BioSpace
Five new Travere hires get stock awards totaling 17,420 shares - Stock Titan
BridgeBio Oncology Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
CCCC Price Today: C4 Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
C4 Therapeutics Faces Ownership Changes Amidst Financial Declines - StocksToTrade
Travel Stocks: Can C4 Therapeutics Inc reach all time highs this year2026 Earnings & Safe Investment Capital Preservation Plans - baoquankhu1.vn
C4 Therapeutics Ownership Changes Raise Investor Concerns - timothysykes.com
Vera Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Amends By-laws to Designate Federal Courts as Exclusive Forum for Securities Act Claims - Minichart
C4 Therapeutics updates bylaws to designate federal courts as exclusive forums - Investing.com
C4 Therapeutics (NASDAQ: CCCC) narrows forums for securities lawsuits - Stock Titan
C 4 Therapeutics Inc (CCCC) 財務データ
収益
当期純利益
現金流量
EPS
C 4 Therapeutics Inc (CCCC) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| REYNO LEONARD | Chief Medical Officer |
Jan 16 '26 |
Sale |
2.22 |
10,000 |
22,200 |
156,382 |
2.45%
大文字化:
|
ボリューム (24 時間):